Cybin posts second-quarter loss widens as clinical trials advance

Green Market Report
By Adam JacksonNov 14, 2024, 12:50 pm179 ptsTop
Toronto-based Cybin Inc. (NYSE: CYBN) reported financials for its fiscal second quarter 2025 ending Sept. 30, with higher R&D costs from its clinical programs. The company also announced it has initiated a phase 3 program evaluating its psilocin-based CYB003 for the adjunctive treatment of major depressive…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

BC Indigenous group thanks Enderby pot shop for making the holidays brighter 69

Green Thumb & Agrify supply staple Chicago music venue with THC goods 68

Michigan Cannabis Sales Decrease in December 67

Tilray reports $65.7 million from cannabis sales in Q2 2025 65

New Data Shows Adult-Use Cannabis Legalization Corresponds with Drops in Teen Use 63

President honors Soros, ‘father’ of marijuana reform laws 63

4 New York Dispensary Licensees Sue State Regulators Over Buffer Rule 60

About NewsBudz

NewsBudz is a marijuana and medical cannabis news app. The site delivers a daily feed of the latest cannabis news. We aggregate over 30 of the web's best sources for news about marijuana, hemp and legalization to keep you informed.

Stay on top of the latest news headlines, trends and developments worldwide around recreational and medical marijuana. Sit back and relax, while you read learn and share. On the web or your mobile device, NewsBudz is your cannabis news stream.